Bristol-Myers Squibb (NYSE:BMY) was downgraded by research analysts at Vetr from a “hold” rating to a “sell” rating in a report released on Thursday. They presently have a $60.72 price target on the biopharmaceutical company’s stock. Vetr‘s target price indicates a potential downside of 3.16% from the stock’s previous close.
BMY has been the topic of a number of other reports. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Citigroup upped their target price on shares of Bristol-Myers Squibb to $72.00 and gave the company a “buy” rating in a research report on Wednesday, October 18th. BMO Capital Markets set a $49.00 price target on Bristol-Myers Squibb and gave the company a “sell” rating in a research note on Thursday, October 12th. Barclays upped their price target on Bristol-Myers Squibb from $58.00 to $65.00 and gave the company an “equal weight” rating in a research note on Friday, October 13th. Finally, Credit Suisse Group set a $62.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, January 22nd. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $65.58.
Bristol-Myers Squibb (NYSE:BMY) traded up $0.01 during trading on Thursday, reaching $62.70. 11,131,473 shares of the company’s stock were exchanged, compared to its average volume of 8,430,000. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb has a 52 week low of $51.52 and a 52 week high of $66.10. The firm has a market cap of $102,620.00, a P/E ratio of 106.27, a PEG ratio of 1.95 and a beta of 1.08.
In related news, EVP Sandra Leung sold 156,582 shares of the stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Theodore R. Samuels II bought 4,000 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were acquired at an average cost of $62.30 per share, with a total value of $249,200.00. Following the completion of the purchase, the director now owns 22,000 shares in the company, valued at approximately $1,370,600. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Delphi Private Advisors LLC bought a new stake in Bristol-Myers Squibb during the 4th quarter worth approximately $108,000. Massey Quick Simon & CO. LLC increased its stake in Bristol-Myers Squibb by 523.5% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 1,492 shares in the last quarter. Horan Capital Advisors LLC. bought a new position in shares of Bristol-Myers Squibb during the 3rd quarter worth approximately $122,000. NuWave Investment Management LLC bought a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $119,000. Finally, Tradewinds Capital Management LLC grew its stake in shares of Bristol-Myers Squibb by 34.6% during the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 500 shares in the last quarter. 69.70% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Bristol-Myers Squibb (BMY) Downgraded by Vetr to “Sell”” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/02/11/bristol-myers-squibb-bmy-downgraded-by-vetr-to-sell.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.